Rating of medication influences (ROMI) scale in schizophrenia
Peter Weiden, Bruce D. Rapkin, Tasha Mott, Annette Zygmunt, Dodi Goldman, Marcela Horvitz-lennon, Allen Frances
Noncompliance with neuroleptic treatment is a major barrier to delivery of effective treatment for schizophrenia outpatients. This article describes the development of a standardized measure for the assessment of attitudinal and behavioral factors influencing patient compliance with neuroleptic treatment. The Rating of Medication Influences (ROMI) scale was developed as part of a longitudinal study of neuroleptic noncompliance in schizophrenia and administered to 115 discharged schizophrenia outpatients. Analyses of the following were conducted to assess the scale's psychometric properties: (1) interrater reliability, (2) internal consistency, (3) principal components, (4) correlation with other subjective measures, and (5) correlation with independent family reports. Most (95%) of the ROMI patient-report items were reliable, whereas rater-judgment items were not reliable. The rater section was dropped. A principal components analysis of the reliable patient-report items yielded three subscales related to compliance (Prevention, Influence of Others, and Medication Affinity) and five subscales related to noncompliance (Denial/Dysphoria, Logistical Problems, Rejection of Label, Family Influence, and Negative Therapeutic Alliance). There were significant correlations between these subscales, and independently obtained family-report ROMI items were significant. The Denial/Dysphoria subscale correlated strongly with two other published measures of dysphoric response to neuroleptics, whereas the other noncompliance sub-scales did not. The ROMI is a reliable and valid instrument that can be used to assess the patient's subjective reasons for medication compliance and noncompliance. The subscale findings suggest that the ROMI provides a more comprehensive data base for patient-reported compliance attitudes than the other available subjective measures. Indications for use of the ROMI and other subjective measures of neuroleptic response are reviewed.
Schizophrenia Bulletin
https://doi.org/10.1093/schbul/20.2.297
Patient Compliance
principal components analysis
Weiden, P., Rapkin, B. D., Mott, T., Zygmunt, A., Goldman, D., Horvitz-lennon, M., & Frances, A. (1994). Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin, 20(2), 297-310. https://doi.org/10.1093/schbul/20.2.297
Rating of medication influences (ROMI) scale in schizophrenia. / Weiden, Peter; Rapkin, Bruce D.; Mott, Tasha; Zygmunt, Annette; Goldman, Dodi; Horvitz-lennon, Marcela; Frances, Allen.
In: Schizophrenia Bulletin, Vol. 20, No. 2, 1994, p. 297-310.
Weiden, P, Rapkin, BD, Mott, T, Zygmunt, A, Goldman, D, Horvitz-lennon, M & Frances, A 1994, 'Rating of medication influences (ROMI) scale in schizophrenia', Schizophrenia Bulletin, vol. 20, no. 2, pp. 297-310. https://doi.org/10.1093/schbul/20.2.297
Weiden P, Rapkin BD, Mott T, Zygmunt A, Goldman D, Horvitz-lennon M et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin. 1994;20(2):297-310. https://doi.org/10.1093/schbul/20.2.297
Weiden, Peter ; Rapkin, Bruce D. ; Mott, Tasha ; Zygmunt, Annette ; Goldman, Dodi ; Horvitz-lennon, Marcela ; Frances, Allen. / Rating of medication influences (ROMI) scale in schizophrenia. In: Schizophrenia Bulletin. 1994 ; Vol. 20, No. 2. pp. 297-310.
@article{4a0de4b1085b4ee0a91077a354ad3b2b,
title = "Rating of medication influences (ROMI) scale in schizophrenia",
abstract = "Noncompliance with neuroleptic treatment is a major barrier to delivery of effective treatment for schizophrenia outpatients. This article describes the development of a standardized measure for the assessment of attitudinal and behavioral factors influencing patient compliance with neuroleptic treatment. The Rating of Medication Influences (ROMI) scale was developed as part of a longitudinal study of neuroleptic noncompliance in schizophrenia and administered to 115 discharged schizophrenia outpatients. Analyses of the following were conducted to assess the scale's psychometric properties: (1) interrater reliability, (2) internal consistency, (3) principal components, (4) correlation with other subjective measures, and (5) correlation with independent family reports. Most (95{\%}) of the ROMI patient-report items were reliable, whereas rater-judgment items were not reliable. The rater section was dropped. A principal components analysis of the reliable patient-report items yielded three subscales related to compliance (Prevention, Influence of Others, and Medication Affinity) and five subscales related to noncompliance (Denial/Dysphoria, Logistical Problems, Rejection of Label, Family Influence, and Negative Therapeutic Alliance). There were significant correlations between these subscales, and independently obtained family-report ROMI items were significant. The Denial/Dysphoria subscale correlated strongly with two other published measures of dysphoric response to neuroleptics, whereas the other noncompliance sub-scales did not. The ROMI is a reliable and valid instrument that can be used to assess the patient's subjective reasons for medication compliance and noncompliance. The subscale findings suggest that the ROMI provides a more comprehensive data base for patient-reported compliance attitudes than the other available subjective measures. Indications for use of the ROMI and other subjective measures of neuroleptic response are reviewed.",
author = "Peter Weiden and Rapkin, {Bruce D.} and Tasha Mott and Annette Zygmunt and Dodi Goldman and Marcela Horvitz-lennon and Allen Frances",
doi = "10.1093/schbul/20.2.297",
journal = "Schizophrenia Bulletin",
T1 - Rating of medication influences (ROMI) scale in schizophrenia
AU - Weiden, Peter
AU - Rapkin, Bruce D.
AU - Mott, Tasha
AU - Zygmunt, Annette
AU - Goldman, Dodi
AU - Horvitz-lennon, Marcela
AU - Frances, Allen
N2 - Noncompliance with neuroleptic treatment is a major barrier to delivery of effective treatment for schizophrenia outpatients. This article describes the development of a standardized measure for the assessment of attitudinal and behavioral factors influencing patient compliance with neuroleptic treatment. The Rating of Medication Influences (ROMI) scale was developed as part of a longitudinal study of neuroleptic noncompliance in schizophrenia and administered to 115 discharged schizophrenia outpatients. Analyses of the following were conducted to assess the scale's psychometric properties: (1) interrater reliability, (2) internal consistency, (3) principal components, (4) correlation with other subjective measures, and (5) correlation with independent family reports. Most (95%) of the ROMI patient-report items were reliable, whereas rater-judgment items were not reliable. The rater section was dropped. A principal components analysis of the reliable patient-report items yielded three subscales related to compliance (Prevention, Influence of Others, and Medication Affinity) and five subscales related to noncompliance (Denial/Dysphoria, Logistical Problems, Rejection of Label, Family Influence, and Negative Therapeutic Alliance). There were significant correlations between these subscales, and independently obtained family-report ROMI items were significant. The Denial/Dysphoria subscale correlated strongly with two other published measures of dysphoric response to neuroleptics, whereas the other noncompliance sub-scales did not. The ROMI is a reliable and valid instrument that can be used to assess the patient's subjective reasons for medication compliance and noncompliance. The subscale findings suggest that the ROMI provides a more comprehensive data base for patient-reported compliance attitudes than the other available subjective measures. Indications for use of the ROMI and other subjective measures of neuroleptic response are reviewed.
AB - Noncompliance with neuroleptic treatment is a major barrier to delivery of effective treatment for schizophrenia outpatients. This article describes the development of a standardized measure for the assessment of attitudinal and behavioral factors influencing patient compliance with neuroleptic treatment. The Rating of Medication Influences (ROMI) scale was developed as part of a longitudinal study of neuroleptic noncompliance in schizophrenia and administered to 115 discharged schizophrenia outpatients. Analyses of the following were conducted to assess the scale's psychometric properties: (1) interrater reliability, (2) internal consistency, (3) principal components, (4) correlation with other subjective measures, and (5) correlation with independent family reports. Most (95%) of the ROMI patient-report items were reliable, whereas rater-judgment items were not reliable. The rater section was dropped. A principal components analysis of the reliable patient-report items yielded three subscales related to compliance (Prevention, Influence of Others, and Medication Affinity) and five subscales related to noncompliance (Denial/Dysphoria, Logistical Problems, Rejection of Label, Family Influence, and Negative Therapeutic Alliance). There were significant correlations between these subscales, and independently obtained family-report ROMI items were significant. The Denial/Dysphoria subscale correlated strongly with two other published measures of dysphoric response to neuroleptics, whereas the other noncompliance sub-scales did not. The ROMI is a reliable and valid instrument that can be used to assess the patient's subjective reasons for medication compliance and noncompliance. The subscale findings suggest that the ROMI provides a more comprehensive data base for patient-reported compliance attitudes than the other available subjective measures. Indications for use of the ROMI and other subjective measures of neuroleptic response are reviewed.
U2 - 10.1093/schbul/20.2.297
DO - 10.1093/schbul/20.2.297
JO - Schizophrenia Bulletin
JF - Schizophrenia Bulletin
10.1093/schbul/20.2.297